Press Releases
Mar. 26, 2026
Russia Issues Warning to Japan Over Ukraine Arms Supplies
Indeterminate
MENAFN
Owner: Sawsan Dababneh
Mar. 26, 2026
Over 600 Affected by Food Poisoning in Japan Schools
Indeterminate
MENAFN
Owner: Sawsan Dababneh
Mar. 25, 2026
Valentine’s Matcha Launches with Premium Japanese Matcha for Cooking, Baking and Daily Drink Rituals
Neutral
EIN Presswire
Mar. 25, 2026
Tower Semiconductor and Nuvoton Technology Corporation Japan Announce Strategic Business Restructuring of TPSCo
Indeterminate
GlobeNewswire, Inc.
Mar. 25, 2026
Tower Semiconductor Announces Plans to Expand 300mm Capacity in Japan to Support Strong Customer Demand
Indeterminate
GlobeNewswire, Inc.
Mar. 25, 2026
President Lai meets Japan-Taiwan Friendship Association Chairman Eto Seishiro
Gov't Institution
Taiwan President News
Owner: Taiwanese Government
Mar. 25, 2026
Amogy and Hoku Infrastructure Partner to Advance Ammonia-to-Power Projects for Data Centers in Japan
Indeterminate
GlobeNewswire, Inc.
Mar. 25, 2026
X Refuses Japan’s Appeal to Lengthen Data Storage Period
Indeterminate
MENAFN
Owner: Sawsan Dababneh
Mar. 25, 2026
South Korea Lodges Protest Over Japan’s Renewed Islet Claims
Indeterminate
MENAFN
Owner: Sawsan Dababneh
Mar. 25, 2026
povo Adds New Plans to Data-Only eSIM 'Japan SIM' Lineup for international Visitors to Japan
Neutral
EIN Presswire
Mar. 25, 2026
povo Adds New Plans to Data-Only eSIM 'Japan SIM' Lineup for international Visitors to Japan
Neutral
EIN Presswire
Mar. 24, 2026
Multilingual Houwa Video from Japan’s H1 Houwa Grand Prix to Premiere Worldwide on YouTube on April 1
Neutral
EIN Presswire
Mar. 24, 2026
Beyond the Northern Sea Route: The Developmental State and Japanese Arctic Energy Policy
Indeterminate
The Arctic Institute
Owner: The Arctic Institute (Non-profit)
Mar. 24, 2026
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Indeterminate
GlobeNewswire, Inc.
24 minutes ago
Nuclear Medicine Market Size to Hit US$ 28.6 Bn by 2033, Expanding at 11.2% CAGR | Persistence Market Research
Neutral
EIN Presswire
Mar. 24, 2026
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Indeterminate
GlobeNewswire, Inc.